CPHI vs NBIX · rev $4.1M vs P/E 45, rev $2.36B
China Pharma Holdings Inc (CPHI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CPHI currently screens at market cap $29.0M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CPHI and NBIX stock pages for the full models.
Not investment advice.